Business Context and Reporting Period
This Form 8-K is filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on May 20, 2021. The report serves to announce the Company's financial results for the quarter ended March 31, 2021, along with other recent corporate updates. The Company is an emerging growth company incorporated in Delaware, with its common stock (RPHM) trading on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main text. It directs readers to the press release (Exhibit 99.1) for the specific financial results and corporate updates.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (RPHM), as the input metadata incorrectly listed "Onkure Therapeutics, Inc."
- Review Exhibit 99.1 (the Press Release) to obtain actual financial figures for the quarter ended March 31, 2021, as they are absent from the 8-K text.
- Confirm the status of the Company as an emerging growth company and its implications for financial reporting standards.
- Note that the financial data in this filing is not "filed" under Section 18 of the Exchange Act, limiting liability protections for the disclosed information.